Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353531 | PMC |
| http://dx.doi.org/10.1002/mdc3.12055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The degeneration of midbrain dopamine (DA) neurons disrupts the neural control of natural behavior, such as walking, posture, and gait in Parkinson's disease. While some aspects of motor symptoms can be managed by dopamine replacement therapies, others respond poorly. Recent advancements in machine learning-based technologies offer opportunities for unbiased segmentation and quantification of natural behavior in both healthy and diseased states.
View Article and Find Full Text PDFAttenuated afferent inhibition correlated with impaired gait performance in Parkinson's disease patients with freezing of gait.
Front Aging Neurosci
December 2024
Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: The neural mechanisms underlying freezing of gait (FOG) in Parkinson's disease (PD) have not been completely comprehended. Sensory-motor integration dysfunction was proposed as one of the contributing factors. Here, we investigated short-latency afferent inhibition (SAI) and long-latency afferent inhibition (LAI), and analyzed their association with gait performance in FOG PD patients, to further validate the role of sensorimotor integration in the occurrence of FOG in PD.
View Article and Find Full Text PDFEthylenediamine assist preparation of carbon dots with novel biomass for highly sensitive detection of levodopa.
RSC Adv
January 2025
Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Collaborative Innovation Center of One Health, Hainan University Haikou 570228 China
Levodopa (l-Dopa), a precursor drug for dopamine has been widely used to treat Parkinson's disease. However, excess accumulation of l-Dopa in the body may cause movement disorders and uncontrollable emotions. Therefore, it is vital to monitor l-Dopa levels in patients.
View Article and Find Full Text PDFC19orf12 gene variants causing mitochondrial membrane protein-associated neurodegeneration (MPAN).
Eur J Hum Genet
January 2025
Institute of Bioinformatics, International Technology Park, Bangalore, 560066, India.
Mitochondrial membrane protein-associated neurodegeneration (MPAN) is a rare neurodegenerative disorder characterized by spastic paraplegia, parkinsonism and psychiatric and/or behavioral symptoms caused by variants in gene encoding chromosome-19 open reading frame-12 (C19orf12). We present here seven patients from six unrelated families with detailed clinical, radiological, and genetic investigations. Childhood-onset patients predominantly had a spastic ataxic phenotype with optic atrophy, while adult-onset patients were presented with cognitive, behavioral, and parkinsonian symptoms.
View Article and Find Full Text PDFDevelopment of a liquid chromatography-mass spectrometry based targeted metabolomics method for discovering diagnostic biomarkers in Kawasaki disease.
J Chromatogr A
December 2024
Shanghai Center for Clinical Laboratory, Shanghai, PR China. Electronic address:
Kawasaki disease (KD) has emerged as the leading cause of acquired heart disease in children, primarily due to the absence of highly sensitive and specific biomarkers for early and accurate diagnosis. To address this issue, a simple and comprehensive targeted metabolomics method employing ultra high-performance liquid chromatography coupled with Q-TRAP mass spectrometry has been developed to identify new metabolite biomarkers for KD. This method enables the simultaneous quantification of 276 metabolites, covering 60 metabolic pathways, with a particular emphasis on metabolites relevant to KD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!